OR-LATTICE-SEMICONDUCTOR
12.8.2020 22:02:08 CEST | Business Wire | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the Lattice Sentry™ solutions stack and the Lattice SupplyGuard™ supply chain protection service. The Sentry stack is a robust combination of customizable embedded software, reference designs, IP, and development tools to accelerate the implementation of secure systems compliant with NIST Platform Firmware Resiliency (PFR) Guidelines (NIST SP-800-193). The Lattice SupplyGuard service extends the system protection provided by the Sentry stack throughout today’s challenging and rapidly changing supply chain by delivering factory-locked devices to protect them from attacks like cloning and malware insertion, and enables secure device ownership transfer. These hardware security solutions are increasingly important to a range of applications, including communications, datacenter, industrial, automotive, aerospace, and client computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005214/en/
According to Patrick Moorhead, president and founder of Moor Insights & Strategy, “5G, Edge computing, and IoT are accelerating the pace at which devices are becoming connected, and security concerns are on the rise among high-tech OEMs serving every market. Developers need to know their hardware platforms are secured against cyberattack and IP theft. They need security solutions that support comprehensive protection throughout a product’s entire operating life in the field, which means the solution must be able to dynamically adapt to an evolving threat landscape.”
“Lattice continues to execute to our solutions stack roadmap and strategy to provide our customers with easy to use, system-level solutions for key focus applications. The Lattice Sentry solutions stack makes it easy for customers to implement a hardware Root-of-Trust (RoT)-based PFR solution compliant with the NIST SP-800-193 guidelines,” said Deepak Boppana, Sr. Director, Segments and Solutions Marketing, Lattice. “With Sentry’s validated IPs, pre-verified reference designs, and hardware demos, developers can quickly customize the PFR solution by modifying the C code provided with the RISC-V and Propel design environment to cut time-to-market from ten months to just six weeks.”
The security paradigm is changing, and firmware is an increasingly popular attack vector. The National Vulnerability Database reported that between 2016 and 2019 the number of firmware vulnerabilities grew over 700 percent1 . Protecting systems against unauthorized firmware access requires dynamic, persistent, real-time hardware platform security for all connected devices. This includes securing component firmware from unauthorized access and enabling the system to automatically protect, detect, and recover from an attack in an instant. TPM and MCU-based hardware security solutions use serial processing and cannot deliver the real-time performance that parallel processing solutions like Lattice FPGAs can.
“To provide them with peace of mind in a constantly changing and increasingly risky supply chain environment, Lattice developed our SupplyGuard service to help our customers securely provision their devices while lowering their overall costs,” said Eric Sivertson, Vice President of Security Business, Lattice. “With Sentry and SupplyGuard, Lattice delivers comprehensive, truly parallel, nanosecond reactive, next-generation security to enable dynamic trust for our customers and the users of their products.”
Key features of the Lattice Sentry solutions stack include:
- Hardware security capabilities – the Sentry solutions stack provides a pre-verified, NIST-compliant PFR implementation that enforces strict, real-time access controls to all system firmware during and after system boot. If corrupt firmware is detected, Sentry can automatically rollback to a previously known good state version of the firmware so secure system operation continues without interruption.
- Compliance with latest NIST SP-800-193 standard and CAVP certifications – the stack enables implementation of a hardware RoT through its support for the cryptographically-sound Lattice MachXO3D™ family of FPGAs.
- Ease of use – developers can drag-and-drop Sentry’s validated IPs and modify the included RISC-V C reference code in the Lattice Propel design environment without any prior FPGA experience.
- Rapid time-to-market – the Sentry stack provides pre-verified and tested application demos, reference designs, and development boards that can slash development times for PFR applications from ten months to just six weeks.
- Flexible, platform-agnostic security solution – Sentry offers comprehensive, real-time PFR support for firmware and programmable peripherals. It can act as a RoT in a system and/or complement any existing BMC/MCU/TPM-based architecture for full NIST SP-800-193 compliance.
Key features of the Lattice SupplyGuard supply chain protection service include:
-
Robust security throughout device lifecycle – SupplyGuard is a subscribed service that offers OEMs and ODMs peace of mind by tracking locked Lattice FPGAs through their entire lifecycle, from the point of manufacture, through transport through the global supply chain, system integration and assembly, initial configuration, and deployment. SupplyGuard helps protect OEMs by:
- Ensuring only authorized manufacturers can build an OEM’s design, regardless of their location.
- Providing OEMs with a secure key infrastructure to prevent the activation of their IP on unauthorized components to stop product cloning and overbuilding.
- Securing devices against the download and installation of Trojans, malware, or other unauthorized software to protect platforms and systems against equipment hijacking or other cyberattacks.
- Flexible, low-cost implementation – SupplyGuard is highly customizable to meet the specific security and supply chain needs of OEMs in every industry Lattice serves. The service lowers the operating costs associated with implementing a secure manufacturing ecosystem.
For more information, please visit www.latticesemi.com/LatticeSentry and www.latticesemi.com/LatticeSupplyGuard
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.
For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo or Youku .
Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
1 Source: National Vulnerability Database (2016 and 2019 )
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005214/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
